Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Extremely Severe CD4 Lymphopenia During HIV-1 Primary Infection.

Bonnet B, Blum L, Charpentier C, Martres P, Ritvo PG, Autran B, Guihot A.

AIDS Res Hum Retroviruses. 2019 Sep 12. doi: 10.1089/AID.2019.0065. [Epub ahead of print]

PMID:
31418284
2.

Development, implementation, and effects of a cancer center's exercise-oncology program.

Santa Mina D, Au D, Auger LE, Alibhai SMH, Matthew AG, Sabiston CM, Oh P, Ritvo PG, Chang EB, Jones JM.

Cancer. 2019 Oct 1;125(19):3437-3447. doi: 10.1002/cncr.32297. Epub 2019 Jun 17.

PMID:
31206630
3.

Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells.

Ritvo PG, Klatzmann D.

Front Immunol. 2019 Feb 27;10:250. doi: 10.3389/fimmu.2019.00250. eCollection 2019. Review.

4.

High-resolution repertoire analysis reveals a major bystander activation of Tfh and Tfr cells.

Ritvo PG, Saadawi A, Barennes P, Quiniou V, Chaara W, El Soufi K, Bonnet B, Six A, Shugay M, Mariotti-Ferrandiz E, Klatzmann D.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9604-9609. doi: 10.1073/pnas.1808594115. Epub 2018 Aug 29.

5.

Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2.

Churlaud G, Abbara C, Vinot PA, Fourcade G, Ritvo PG, Lorenzon R, Rosenzwajg M, Diquet B, Klatzmann D.

J Allergy Clin Immunol. 2018 Oct;142(4):1344-1346.e3. doi: 10.1016/j.jaci.2018.06.006. Epub 2018 Jun 18. No abstract available.

6.

Tfr cells lack IL-2Rα but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of Tfh cells.

Ritvo PG, Churlaud G, Quiniou V, Florez L, Brimaud F, Fourcade G, Mariotti-Ferrandiz E, Klatzmann D.

Sci Immunol. 2017 Sep 8;2(15). pii: eaan0368. doi: 10.1126/sciimmunol.aan0368.

PMID:
28887367
7.

Personal navigation increases colorectal cancer screening uptake.

Ritvo PG, Myers RE, Paszat LF, Tinmouth JM, McColeman J, Mitchell B, Serenity M, Rabeneck L.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):506-11. doi: 10.1158/1055-9965.EPI-14-0744. Epub 2014 Nov 6.

8.

Exercise in clinical cancer care: a call to action and program development description.

Santa Mina D, Alibhai SM, Matthew AG, Guglietti CL, Steele J, Trachtenberg J, Ritvo PG.

Curr Oncol. 2012 Jun;19(3):e136-44. doi: 10.3747/co.19.912.

10.

The efficiency and effectiveness of utilizing diagrams in interviews: an assessment of participatory diagramming and graphic elicitation.

Umoquit MJ, Dobrow MJ, Lemieux-Charles L, Ritvo PG, Urbach DR, Wodchis WP.

BMC Med Res Methodol. 2008 Aug 8;8:53. doi: 10.1186/1471-2288-8-53.

11.

Prevalence and correlates of successful transfer from pediatric to adult health care among a cohort of young adults with complex congenital heart defects.

Reid GJ, Irvine MJ, McCrindle BW, Sananes R, Ritvo PG, Siu SC, Webb GD.

Pediatrics. 2004 Mar;113(3 Pt 1):e197-205.

PMID:
14993577
12.

Recent developments in the assessment of quality of life in multiple sclerosis (MS).

Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D.

Mult Scler. 1999 Aug;5(4):251-9. Review.

PMID:
10467384
13.

Critique of the National Cancer Institute of Canada's framework for cancer control.

Cameron AJ, Brown KS, Cohen RS, Leis AM, Manske S, Olson K, Ritvo PG.

Cancer Prev Control. 1997 Dec;1(5):361-5.

PMID:
9765758
14.

A critical review of research related to family physician-assisted smoking cessation interventions.

Ritvo PG, Irvine MJ, Lindsay EA, Kraetschmer N, Blair N, Shnek ZM.

Cancer Prev Control. 1997 Oct;1(4):289-303. Review.

PMID:
9765753
15.

Conceptual reasoning as a mediator of verbal recall in patients with multiple sclerosis.

Troyer AK, Fisk JD, Archibald CJ, Ritvo PG, Murray TJ.

J Clin Exp Neuropsychol. 1996 Apr;18(2):211-9.

PMID:
8780956
16.

Psychosocial and neurological predictors of mental health in multiple sclerosis patients.

Ritvo PG, Fisk JD, Archibald CJ, Murray TJ, Field C.

J Clin Epidemiol. 1996 Apr;49(4):467-72. No abstract available.

PMID:
8621999
17.

Quality of life and prostate cancer treatment: decision-making and rehabilitative support.

Ritvo PG.

Can J Oncol. 1994 Nov;4 Suppl 1:43-5; discussion 46. No abstract available.

PMID:
8853489
18.

Functional competence of community-dwelling persons with multiple sclerosis using the assessment of motor and process skills.

Doble SE, Fisk JD, Fisher AG, Ritvo PG, Murray TJ.

Arch Phys Med Rehabil. 1994 Aug;75(8):843-51.

PMID:
8053789
19.

Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients.

Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, Murray TJ.

Pain. 1994 Jul;58(1):89-93.

PMID:
7970843
20.

The impact of fatigue on patients with multiple sclerosis.

Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ.

Can J Neurol Sci. 1994 Feb;21(1):9-14.

PMID:
8180914
21.

Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF.

Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83.

PMID:
8148458
22.

Anal sphincter biofeedback relaxation treatment for women with intractable constipation symptoms.

Turnbull GK, Ritvo PG.

Dis Colon Rectum. 1992 Jun;35(6):530-6.

PMID:
1587169

Supplemental Content

Loading ...
Support Center